Friday, April 24, 2026-Two experimental drugs are generating rare optimism in the fight against pancreatic cancer, one of the deadliest and most difficult-to-treat forms of the disease.
In separate clinical trials, both treatments have shown the potential to significantly extend survival, offering what researchers describe as a meaningful shift after decades of limited progress.
One of the drugs, a daily oral therapy developed by Revolution Medicines, targets a key cancer-driving mutation in the KRAS gene. In a late-stage trial, patients taking the drug lived a median of about 13 months compared with roughly 6 to 7 months for those receiving standard chemotherapy.
The results suggest the treatment can slow tumor growth and improve survival in patients whose disease has long been considered highly resistant to targeted therapies.
The second drug, developed by Actuate Therapeutics, is given intravenously and works by weakening tumor defenses and improving the effectiveness of chemotherapy.
Early and mid-stage trial results showed that patients receiving the combination were nearly twice as likely to be alive after one year compared with chemotherapy alone, alongside a significant reduction in risk of death.
Together, the findings are being viewed as a turning point in pancreatic cancer research. Experts caution that larger trials are still needed, but say the results signal a new era in which multiple targeted therapies could be used in sequence or combination, potentially transforming outcomes for a disease that has long carried a grim prognosis.
0 Comments